- Dose range
- 2 → 12 mg/wk
- Route
- Subcutaneous injection, once weekly
- Indication(s)
- Phase 3 obesity (TRIUMPH); not yet FDA-approved
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| 1 | 2 mg/week | Weeks 1-4 | Investigational only |
| 2 | 4 mg/week | Weeks 5-8 | |
| 3 | 8 mg/week | Weeks 9-16 | |
| 4 | 12 mg/week | Week 17+ | TRIUMPH-1 maintenance |
Important notes
- This research compound dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- Research compound; not FDA-approved for any indication. Off-label or experimental use only.
- FDA states (page current as of October 1, 2026) that this compound cannot be used in compounding under federal law; it is available only inside clinical trials.
References
- Retatrutide (investigational) prescribing information / clinical literature.
- FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.